NVIV News and Press, InVivo Therapeutics Holdings Corp. From 03/06/20

TransEnterix (NYSEMKT: TRXC )  -57%  after pricing equity offering. More news on: TransEnterix, Inc., American Outdoor Brands Corporation, Bionano Genomics, Inc., Stocks on the move, , Read more ...

InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 2,545,455 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effec...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-30 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on February 11, ...

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, b...

InVivo Therapeutics Holdings (NASDAQ: NVIV ) has priced its public offering of 7M common shares at $0.12 per share, for expected gross proceeds of $840,000. More news on: InVivo Therapeutics Holdings Corp., Healthcare stocks news, Stocks on the move, Read more ...

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are expected to be $840,000, before de...

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether...

InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019. Dr. Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and busines...

- First Five Patients Enrolled into Study, Reaching 25% Completion of Targeted Enrollment – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a total of five patients have been enrolled into The INSPIRE 2.0 Study ( In Vivo Study of Probable Benefit of the Neur...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a manuscript in the peer-reviewed journal Spinal Cord describing its CONTEMPO registry study data. The CONTEMPO registry study, part of the Company’s IDE submission for the Neuro-Spinal Scaffold&#...